Neuren already completed a pediatric study and met multiple stat significant endpoints. Thats my point, and the FDA is requiring a now 13 month old pivotal P3 with well over 100 patients that reads out next year. Hopefully anavex gets great readouts in the coming months. If anavex somehow avoids a larger trial then that would be surprising but no realistic way to say Neuren isn't in the lead to be first on the market imo.
News 
Market Data 
Discover 
